Discovering significant breakthroughs in fibrosis.

Blade Clinical Trials

Today, we are advancing a robust pipeline of potential first-in-class investigational small-molecule therapies to combat diseases of lung, liver and heart fibrosis, as well as neuro-degenerative conditions. This includes multiple direct inhibitors of autotaxin / LPA and dimeric calpains that offer distinct but complementary anti-fibrotic mechanisms.

Find Clinical Trials Near Me

Program Indication Study Phase Status Trial number
BLD-0409 Healthy Volunteer Safety Testing Phase 1 Complete NCT04146805
BLD-0409-102 Relative Bioavailability Phase 1b In Process NCT04814472
BLD-0409-103 Drug-Drug Interaction Phase 1b In Process NCT04814498
BLD-0409-203 Idiopathic Pulmonary Fibrosis Phase 2 Planned  
BLD-0409-210 Interstitial Lung Disease Phase 2 Planned  

Chronic Liver Disease

Blade’s autotaxin inhibitor, BLD-0409, is being studied in a Phase 1 double-blind, randomized, placebo-controlled, multiple cohort, single and multiple ascending dose trial to assess safety, tolerability and pharmacokinetics in healthy participants (Clinicaltrials.gov NCT04146805).